To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

NCT00141479 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Bifeprunox

Sponsor

Solvay Pharmaceuticals

Collaborators

[object Object]
[object Object]